XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information
12.
Segment Information

The CODM reviews the budget versus actual expense by nature of expense. The following table sets forth our segment loss disclosure for the three months ended March 31, 2025 and 2024 (in thousands):

 

 

Three Months Ended
March 31,

 

 

2025

 

 

2024

 

R&D – Compensation and benefits (1)

 

$

3,294

 

 

$

3,487

 

R&D – Clinical trial costs

 

 

2,850

 

 

 

2,596

 

R&D – Outsourced services & Consulting

 

 

2,382

 

 

 

4,679

 

R&D – Lab and pharmacology supplies

 

 

290

 

 

 

704

 

R&D – Other costs (2)

 

 

597

 

 

 

433

 

G&A – Compensation and benefits (1)

 

 

1,574

 

 

 

1,547

 

G&A – Professional service fees

 

 

997

 

 

 

793

 

G&A – Insurance

 

 

218

 

 

 

30

 

G&A – Other costs (3)

 

 

726

 

 

 

372

 

Facilities related

 

 

2,299

 

 

 

652

 

Stock-based compensation and depreciation

 

 

2,114

 

 

 

1,590

 

Total operating expense

 

 

17,341

 

 

 

16,883

 

Loss from operations

 

 

(17,341

)

 

 

(16,883

)

Interest and other income, net

 

 

1,583

 

 

 

1,453

 

Segment net loss

 

$

(15,758

)

 

$

(15,430

)

 

(1)
Excludes stock-based compensation expense.
(2)
Includes software expense, database subscriptions expense, lab service contract expense, travel expense, and other miscellaneous expenses.
(3)
Includes travel expense, public & investor relations expense, software expense, employee training & development expense, and other miscellaneous expenses.